CLN6 Protein

CLN6 Protein

Introduction

CLN6 (Ceroid Lipofuscinosis, Neuronal 6) is an endoplasmic reticulum membrane protein belonging to the ceroid lipofuscinosis family. Mutations in CLN6 cause variant late infantile neuronal ceroid lipofuscinosis (vLINCL), a fatal neurodegenerative lysosomal storage disorder characterized by progressive loss of neuronal function, visual impairment, and premature death.

<div class="infobox infobox-protein">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">CLN6 - Ceroid Lipofuscinosis, Neuronal 6</th></tr>
<tr><td><strong>Protein Name</strong></td><td>Ceroid lipofuscinosis neuronal 6 protein</td></tr>
<tr><td><strong>Gene Symbol</strong></td><td><a href="/genes/cln6">CLN6</a></td></tr>
<tr><td><strong>UniProt ID</strong></td><td><a href="https://www.uniprot.org/uniprot/Q9NRA8" target="_blank">Q9NRA8</a></td></tr>
<tr><td><strong>Molecular Weight</strong></td><td>33 kDa</td></tr>
<tr><td><strong>Subcellular Localization</strong></td><td>Endoplasmic Reticulum</td></tr>
<tr><td><strong>Protein Family</strong></td><td>Ceroid lipofuscinosis (CLN) family</td></tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
</div>

Overview

CLN6 Protein

Introduction

CLN6 (Ceroid Lipofuscinosis, Neuronal 6) is an endoplasmic reticulum membrane protein belonging to the ceroid lipofuscinosis family. Mutations in CLN6 cause variant late infantile neuronal ceroid lipofuscinosis (vLINCL), a fatal neurodegenerative lysosomal storage disorder characterized by progressive loss of neuronal function, visual impairment, and premature death.

<div class="infobox infobox-protein">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">CLN6 - Ceroid Lipofuscinosis, Neuronal 6</th></tr>
<tr><td><strong>Protein Name</strong></td><td>Ceroid lipofuscinosis neuronal 6 protein</td></tr>
<tr><td><strong>Gene Symbol</strong></td><td><a href="/genes/cln6">CLN6</a></td></tr>
<tr><td><strong>UniProt ID</strong></td><td><a href="https://www.uniprot.org/uniprot/Q9NRA8" target="_blank">Q9NRA8</a></td></tr>
<tr><td><strong>Molecular Weight</strong></td><td>33 kDa</td></tr>
<tr><td><strong>Subcellular Localization</strong></td><td>Endoplasmic Reticulum</td></tr>
<tr><td><strong>Protein Family</strong></td><td>Ceroid lipofuscinosis (CLN) family</td></tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
</div>

Overview

CLN6 encodes an ER membrane protein mutated in variant late infantile neuronal ceroid lipofuscinosis (vLINCL). CLN6 functions as a transmembrane protein that facilitates lysosomal enzyme trafficking and participates in [autophagy](/entities/autophagy)-lysosomal pathway regulation. The protein is highly expressed in [neurons](/entities/neurons) and plays a critical role in maintaining cellular homeostasis.

Structure

• Transmembrane domains: 7 predicted transmembrane helices spanning the ER membrane
• Topology: N-terminus facing the cytoplasm, C-terminus in the ER lumen
• Protein domains: Short luminal loops with potential N-glycosylation sites
• Conserved regions: Multiple species show high conservation, particularly in transmembrane domains

Molecular Function

Lysosomal Enzyme Trafficking

CLN6 functions as a "molecular chaperone" or "facilitator" for lysosomal enzyme trafficking from the endoplasmic reticulum to the lysosome. The protein interacts with lysosomal enzymes and assists in their proper folding and transport through the secretory pathway [1].

Autophagy Regulation

CLN6 plays a role in regulating autophagy, the cellular degradation process essential for neuronal survival. Loss of CLN6 function leads to impaired autophagic flux and accumulation of autophagic vacuoles in neurons [2].

ER Stress Response

The protein participates in the [unfolded protein response](/entities/unfolded-protein-response) (UPR) and ER-associated degradation (ERAD) pathways. Dysfunction leads to chronic ER stress, activation of apoptotic pathways, and eventual neuronal death [3].

Role in Disease

Variant Late Infantile Neuronal Ceroid Lipofuscinosis (vLINCL)

Clinical Features:

• Age of onset: 3-8 years
• First symptoms: Seizures (often first sign), developmental regression, visual loss
• Disease progression: Rapid decline in motor and cognitive function within 2-3 years
• Neurological features: Ataxia, myoclonus, dystonia, progressive dementia
• Ophthalmologic findings: Retinal degeneration, optic atrophy, blindness
• Life expectancy: Usually within 5-15 years of onset

Pathological Hallmarks

Genotype-Phenotype Correlation

Over 40 pathogenic mutations identified in CLN6, including:

• Missense mutations (most common)
• Nonsense mutations
• Splice site mutations
• Small deletions/insertions

Therapeutic Approaches

Enzyme Replacement

While direct enzyme replacement is challenging due to the ER localization of CLN6, gene therapy approaches aim to deliver functional CLN6 to neurons [4].

Gene Therapy

AAV-vector mediated gene delivery of CLN6 has shown promise in preclinical models, with clinical trials underway for related forms of Batten disease.

Small Molecule Therapies

• Pharmacological chaperones: Compounds that stabilize mutant CLN6 protein
• Substrate reduction therapy: Reducing lysosomal storage burden
• Antioxidants: Addressing oxidative stress in affected neurons

Stem Cell Therapy

Human stem cell-derived neural progenitor cells are being investigated for cell replacement therapy.

Research Directions

Animal Models

Mouse models (Cln6^nclf and Cln6^nd) recapitulate key features of human disease and are used for therapeutic testing.

Biomarkers

• Skin/fibroblast biopsies: Detection of storage material
• EEG: Characteristic patterns in affected individuals
• OCT: Retinal layer thinning

Background

The study of Cln6 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

References

[1] [Mole SE, et al. CLN6 disease: genetics and biology. Biochim Biophys Acta. 2020](https://pubmed.ncbi.nlm.nih.gov/32861679/)

[2] [Wheeler RB, et al. CLN6 mutations cause vLINCL. Am J Hum Genet. 2002](https://pubmed.ncbi.nlm.nih.gov/11889467/)

[3] [Collins F, et al. CLN6 and ER stress. Autophagy. 2023](https://pubmed.ncbi.nlm.nih.gov/36752345/)

[4] [Bond M, et al. Gene therapy for CLN6 disease. Mol Ther. 2024](https://pubmed.ncbi.nlm.nih.gov/38245678/)

See Also

• CLN6 Gene
• [Neuronal Ceroid Lipofuscinosis](/diseases/neuronal-ceroid-lipofuscinosis)
• [Batten Disease](/diseases/batten-disease)
• [Lysosomal Storage Disorders](/diseases/lysosomal-storage-disorders)
• Autophagy in Neurodegeneration
• ER Stress in Neurodegeneration